Feature 1: Unprecedented Launch
GLP-1 therapies like Mounjaro and Zepbound are rewriting the rules of pharmaceutical launches. From patient-driven demand to social media buzz, these drugs shattered records with billions in sales and millions of prescriptions. Discover how consumer-centric strategies and unmet need transformed these launches into historic blockbusters.
Speaker: Anika LaFazia, Consultant, U.S. Thought Leadership & Innovation, IQVIA
Feature 2: Disease Landscape & Comorbid Markets
Obesity is no longer a lifestyle issue—it’s a chronic condition driving a cascade of comorbidities. Learn how GLP-1 therapies are redefining care models, reducing downstream risks, and creating multi-indication opportunities for pharma in a rapidly evolving market.
Speaker: Eric Foster, Managing Principal, U.S. Market Access Strategy Consulting, IQVIA
Feature 3: Comorbidities Driving Utilization
GLP-1 adoption is accelerating, fueled by patients with multiple comorbidities and expanded coverage. Non-diabetes specialists are prescribing at unprecedented rates, signaling a paradigm shift in obesity care. Explore why these therapies are becoming foundational tools in managing complex conditions.
Speaker: Teddy Landsman, Principal, U.S. Market Access Strategy Consulting, IQVIA
Feature 4: Patient Behavior
Behind the GLP-1 hype lies a challenge: persistency. Many patients abandon therapy early, driven by personal goals, systemic friction, and coverage gaps. Understand how behavior impacts ROI and why integrated care models are key to sustaining outcomes.
Speaker: Jeff Thiesen, Managing Principal, U.S. Market Access Strategy Consulting, IQVIA